Monograph of Chlorpromazine

Introduction

Chlorpromazine, first synthesized in 1950, represents the pioneering member of the phenothiazine class of antipsychotic agents. Over subsequent decades, it has served as a foundational therapeutic in the management of schizophrenia, manic episodes, and various behavioral disorders. Its long history of clinical use has also contributed to a considerable body of pharmacological, toxicological, and therapeutic literature, shaping contemporary psychiatric pharmacotherapy.

Key learning objectives for this chapter include:

• Elucidation of the pharmacodynamic mechanisms underlying chlorpromazine’s antipsychotic activity.
• Comprehension of the pharmacokinetic profile and its clinical implications.
• Recognition of therapeutic indications, dosage strategies, and monitoring parameters.
• Identification of common adverse effects and strategies for mitigation.
• Application of chlorpromazine principles to clinical case scenarios.

Fundamental Principles

Pharmacological Classification

Chlorpromazine is classified as a first‑generation (typical) antipsychotic. It is characterized by high affinity for dopamine D2 receptors and moderate affinity for adrenergic, histaminergic, and muscarinic receptors. This receptor-binding profile accounts for both its therapeutic efficacy and its side‑effect spectrum.

Core Concepts and Definitions

• Half‑life (t_1/2): The time required for plasma concentration to reduce by half.
• Maximum concentration (C_max): Peak plasma level following administration.
• Area under the curve (AUC): Integral of concentration over time, reflecting overall exposure.
• Clearance (Cl): Volume of plasma from which the drug is completely eliminated per unit time.
• Bioavailability (F): Fraction of administered dose reaching systemic circulation.

Theoretical Foundations

The central hypothesis posits that antipsychotic efficacy arises from blockade of dopaminergic neurotransmission within the mesolimbic pathway. Chlorpromazine’s high D2 antagonist activity, combined with its antihistaminic and anticholinergic properties, modifies synaptic transmission, thereby attenuating psychotic symptoms. Moreover, its blockade of alpha‑1 adrenergic receptors contributes to sedative and hypotensive effects, which may be therapeutically useful or problematic, depending on context.

Detailed Explanation

Pharmacodynamics

Chlorpromazine binds reversibly to the high‑affinity state of the D2 receptor, with a dissociation constant (K_i) of approximately 0.2 µM. Competition studies indicate that its affinity for other receptors (H1, muscarinic, α1) is roughly 10–20 fold lower, yet clinically relevant due to cumulative effects. The net therapeutic outcome is a balance between D2 antagonism and modulation of other neurotransmitter systems.

Pharmacokinetics

After oral administration, chlorpromazine is absorbed slowly, reaching peak plasma concentrations (C_max) at 4–6 h. The bioavailability is variable, ranging from 50 % to 70 % due to first‑pass metabolism. The drug undergoes extensive hepatic metabolism via cytochrome P450 isoenzymes (primarily CYP2D6 and CYP3A4), yielding several active and inactive metabolites. The elimination half‑life (t_1/2) is approximately 21 h in healthy adults, but can extend to 30–40 h in patients with hepatic impairment.

The pharmacokinetic equation describing concentration over time for a single dose can be expressed as:

C(t) = C₀ × e^-k_elt

where C₀ is the initial concentration and k_el is the elimination rate constant. The AUC is calculated by:

AUC = Dose ÷ Clearance

Clearance (Cl) can be estimated from the elimination rate constant and volume of distribution (V_d):

Cl = k_el × V_d

Volume of distribution is large (≈ 30–40 L/kg) due to extensive tissue binding, particularly in fatty tissues. This characteristic underlies the drug’s propensity for accumulation with repeated dosing.

Factors Influencing Pharmacokinetics

• Age: Elderly patients often exhibit reduced hepatic clearance, prolonging t_1/2.
• Genetic polymorphisms: CYP2D6 poor metabolizers may experience higher plasma levels, increasing risk of adverse reactions.
• Drug interactions: Concomitant use of CYP3A4 inhibitors (e.g., ketoconazole) can elevate systemic exposure.
• Renal function: While chlorpromazine is primarily hepatically eliminated, severe renal impairment can influence plasma protein binding.
• Food intake: High‑fat meals may delay absorption, shifting C_max to later time points.

Mathematical Relationships in Clinical Dosing

Therapeutic plasma concentration ranges for antipsychotic activity are not strictly defined; however, steady‑state trough levels of 200–400 ng/mL are often cited. Estimating steady‑state concentration (C_ss) can be approximated by:

C_ss ≈ (Dose × F) ÷ (Cl × τ)

where τ denotes dosing interval. Adjustments to dose or interval aim to maintain C_ss within the therapeutic range while minimizing peaks that could precipitate extrapyramidal symptoms.

Clinical Significance

Therapeutic Indications

Chlorpromazine remains a viable option for acute agitation, psychotic depression, and bipolar mania when rapid symptom control is required. Its sedative properties also render it useful in the management of severe anxiety or insomnia in psychiatric patients. In some regions, low‑dose chlorpromazine continues to be prescribed for nausea, vomiting, or migraine prophylaxis, though these uses are less common in contemporary practice.

Practical Applications

• Acute psychosis: Intramuscular injections of 50–100 mg provide rapid onset, with subsequent oral maintenance at 150–300 mg/day.
• Maintenance therapy: Oral doses of 200–400 mg/day, divided into two or three administrations, achieve steady plasma levels while limiting peak concentrations.
• Dose titration: Incremental increases of 50 mg every 2–3 days are typical, with careful monitoring of blood pressure and extrapyramidal signs.

Clinical Examples

In a 45‑year‑old male presenting with acute psychotic agitation, an intramuscular dose of 100 mg chlorpromazine provided rapid sedation within 10 min. Subsequent oral therapy at 200 mg/day led to symptom remission over 5 days, with minimal extrapyramidal manifestations. Monitoring of blood pressure revealed mild orthostatic hypotension, which resolved upon dose adjustment.

Clinical Applications/Examples

Case Scenario 1: Schizophrenia with Orthostatic Hypotension

A 32‑year‑old woman with chronic schizophrenia, stable on 300 mg/day chlorpromazine, developed dizziness upon standing. Orthostatic blood pressure drop of 25 mm Hg systolic was documented. Management involved reducing the dose to 200 mg/day and adding a non‑sedating alpha‑1 agonist. Blood pressure normalized within 48 h, and psychotic symptoms remained controlled.

Case Scenario 2: Extrapyramidal Symptoms in Elderly Patient

An 68‑year‑old man with acute mania received 100 mg intramuscular chlorpromazine and subsequently developed rigidity and bradykinesia. The dose was decreased to 50 mg/day orally, and a low‑dose anticholinergic (benztropine 1 mg) was initiated. Symptoms resolved over 3 days, and the patient returned to baseline functional status.

Problem‑Solving Approaches

• When hypotension occurs, consider dose reduction, addition of alpha‑1 agonists, or switching to a second‑generation antipsychotic with lower antihypertensive activity.
• For extrapyramidal side effects, tapering dose, adding anticholinergic agents, or transitioning to atypical antipsychotics may be warranted.
• When hepatic impairment is evident, reduce maintenance dose by 25–50 % and extend dosing intervals.

Summary/Key Points

• Chlorpromazine is a first‑generation antipsychotic with high D2 antagonist activity and moderate affinity for H1, muscarinic, and α1 receptors.
• Its pharmacokinetic profile features a long half‑life (~21 h), extensive tissue distribution, and hepatic metabolism primarily via CYP2D6 and CYP3A4.
• Therapeutic plasma concentrations are maintained through careful dose titration and monitoring of blood pressure and extrapyramidal signs.
• Common adverse effects include orthostatic hypotension, sedation, anticholinergic symptoms, and extrapyramidal reactions; these may be mitigated by dose adjustment, supportive medications, or switching agents.
• Clinical utility extends beyond psychosis to include agitation control and, in select settings, antiemetic and migraine prophylaxis.

In summary, chlorpromazine remains a valuable pharmacologic tool in psychiatric practice. Its well‑characterized receptor profile, predictable pharmacokinetics, and established clinical experience provide a solid foundation for its continued use, particularly when rapid symptom relief is paramount. Clinicians must remain vigilant regarding its side‑effect profile and adjust therapy accordingly to ensure optimal patient outcomes.

References

1. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
2. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
3. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
4. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.